Trevi Therapeutics, Inc.

TRVI · Nasdaq · SIC 2834: Pharmaceutical Preparations
128
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. Haduvio acts on the cough reflex arc both centrally and periphe...

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionTRVIdiscussed_in_filing Cybersecurity
topic_mentionTRVIdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-172025-12-310001193125-26-110783EDGAR99K words
2025-03-182024-12-310000950170-25-041194EDGAR—
2024-03-202023-12-310000950170-24-034167EDGAR—
2023-03-162022-12-310000950170-23-008472EDGAR—
2022-03-172021-12-310001564590-22-010875EDGAR—
2021-03-252020-12-310001564590-21-015506EDGAR—
2020-03-162019-12-310001564590-20-010996EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001193125-25-280166EDGAR70K words
2025-08-072025-06-300000950170-25-105066EDGAR—
2025-05-082025-03-310000950170-25-067011EDGAR—
2024-11-062024-09-300000950170-24-122355EDGAR—
2024-08-082024-06-300000950170-24-093983EDGAR—
2024-05-072024-03-310000950170-24-054489EDGAR—
2023-11-092023-09-300000950170-23-062063EDGAR—
2023-08-102023-06-300000950170-23-041318EDGAR—
2023-05-112023-03-310000950170-23-021240EDGAR—
2022-11-102022-09-300001564590-22-037385EDGAR—
2022-08-112022-06-300001564590-22-029142EDGAR—
2022-05-122022-03-310001564590-22-019895EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-170001193125-26-110767EDGAR2K words
2026-03-090001193125-26-098676EDGAR—
2025-12-050001193125-25-308769EDGAR—
2025-11-130001193125-25-280149EDGAR—
2025-08-200001563880-25-000005EDGAR—
2025-08-070000950170-25-105011EDGAR—
2025-06-170000950170-25-087486EDGAR—
2025-06-040001193125-25-134913EDGAR—
2025-06-020001193125-25-133273EDGAR—
2025-06-020001193125-25-132890EDGAR—

128 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001563880
TickerTRVI
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: d825e3630390509b9027f32e5ceceeb54cc93114d914b0a4a69c6dbb8da94f37
parent: d486372550c997fd9067d08e4128f9c0c048c7151912ee6d32165f05202eb3db
content hash: a79651739be3fe9898c7b43dee4431ab00a1a1b6cb0d8183d97b655eb40f8bcd
signed: 2026-04-13T04:47:53.571Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf